The Inflation Reduction Act was written in a way that experts believe should insulate it somewhat from recent anti-regulatory decisions from the US Supreme Court.
Drugmakers may have success trying to modify certain elements of the drug price negotiation program, like key Medicare definitions for single-source drug and bona fide marketing.
Medicare’s attempts to adapt older statutes to an evolving health care and technological landscape will likely be more vulnerable, but industry may be wary of challenges that create too much chaos in the courts.

Medicare Rx Negotiation More Insulated From SCOTUS Fallout, But Some Key CMS Decisions Could Be Vulnerable

More from Medicare